Loading...
XSWX
DOCM
Market cap526mUSD
Jul 09, Last price  
8.69CHF
1D
-3.98%
1Q
58.00%
IPO
-94.21%
Name

Zur Rose Group AG

Chart & Performance

D1W1MN
XSWX:DOCM chart
P/E
—
P/S
0.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.87%
Rev. gr., 5y
-5.31%
Revenues
1.12b
+10.57%
488,269,000487,192,000523,306,000910,609,000915,554,000834,418,000879,535,000982,921,0001,207,108,0001,355,539,0001,476,930,0001,726,503,000930,969,000969,462,0001,017,045,0001,124,500,000
Net income
-134m
L+38.20%
3,921,0008,674,0006,156,000-15,464,0007,154,0003,445,000-12,769,000-36,238,000-38,971,000-52,358,000-135,695,000-225,735,000-171,115,00082,280,000-97,253,000-134,400,000
CFO
-88m
L+231.83%
13,960,0002,806,00020,809,0002,004,0007,200,00018,872,000-13,830,000-22,227,000-33,227,000-82,571,000-67,511,000-130,631,000-97,287,000-87,415,000-26,598,000-88,259,000
Earnings
Aug 19, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

DocMorris AG, an enterprise headquartered in Frauenfeld, Switzerland, and founded in 1993, operates a dual business model encompassing e-commerce pharmacies and a wholesale distribution network for medical and pharmaceutical goods. Its market reach extends both within Switzerland and across international borders. The company's diverse offerings include consumer health, beauty, and personal care items, alongside services focused on medication management. Furthermore, DocMorris AG maintains physical pharmacy locations. It directly supplies its products to various clients, including medical professionals, online mail-order pharmacies, and individual consumers, utilizing several distinct brands such as Zur Rose, PromoFarma, TeleClinic, and DocMorris. The organization was initially known as Zur Rose AG before it changed its name to Zur Rose Group AG in May 2015.
URL
https://www.zurrosegroup.com/
IPO date
Jul 06, 2017
Employees
2,283
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT